A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer-Reference-Cited by-同舟云学术

A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer

Published:2021-07 Issue: Volume:29 Page:59-67
ISSN:2666-1683
Container-title:European Urology Open Science
language:en
Short-container-title:European Urology Open Science

Author:

Miyazawa Yoshiyuki^ORCID,Sekine Yoshitaka,Arai Seiji,Nakamura Toshiyuki,Takezawa Yutaka,Shimizu Nobuaki,Matsuo Yasushige,Ogura Haruyuki,Takei Tomoyuki,Suzuki Kazuhiro

Funder

Astellas Pharma

Publisher

Elsevier BV

Subject

Urology

Reference28 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

2. Prostate cancer in Asian man;Ito;Nat Rev Urol,2014

3. Novel agents for castration-resistant prostate cancer: early experience and beyond;Fujimoto;Int J Urol,2016

4. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

5. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum Androgens as Predictive Biomarkers: Results From a Randomized Clinical Trial Comparing Enzalutamide and Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer;Clinical Genitourinary Cancer;2024-12

2. Baseline serum testosterone and differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial;Prostate Cancer and Prostatic Diseases;2024-05-07

3. AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3β,17β-Diol;Cancer Research Communications;2023-09-19

4. The utility of the [−2]pro‐prostate‐specific antigen level as a prognostic marker in patients with castration‐resistant prostate cancer treated with enzalutamide;International Journal of Urology;2023-05-31

5. A prospective study of the relationship between CRPC patient's quality of life after enzalutamide and serum testosterone levels measured via LC‐MS/MS;The Prostate;2023-03-09